Comments are closed.
The rare-disease drugmaker's $8.4 billion bid for rival Synageva includes a 136 percent premium, but Robert Cyran and Reynolds Holding explain why that could make sense.
Breakingviews editors explain how the bank was forced to give investors a belated say on combining the chairman and CEO roles and why Wednesday's annual meeting may put directors on the spot.
New boss Steve Easterbrook cooks up a slow and steady turnaround without much quick-serve red meat for investors. Jeffrey Goldfarb and Kevin Allison discuss.
Breakingviews has published a selection of books for purchase and download.
Edited by Richard Beales
View on mobile device
By Peter Thal Larsen
Read the e-book online
Download PDF (English)
Download PDF (Chinese) (点击下载电子书)
Visit the dedicated webpage (Breakingviews subscribers only)
Edited by Robert Cyran
Edited by John Foley